News
RXRX
6.13
-6.98%
-0.46
Why Recursion Pharmaceuticals Stock Is Sinking Today
The Motley Fool · 19h ago
Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock
Benzinga · 22h ago
Weekly Report: what happened at RXRX last week (0303-0307)?
Weekly Report · 1d ago
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?
The Motley Fool · 2d ago
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip
Benzinga · 2d ago
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today
The Motley Fool · 3d ago
This Biotech Stock Could Be the Best Investment of the Decade
The Motley Fool · 4d ago
Cathie Wood Capitalizes on Pullback in Tempus AI to Buy Additional Stock Worth $14.4M
TipRanks · 4d ago
April 25th Options Now Available For Recursion Pharmaceuticals (RXRX)
NASDAQ · 4d ago
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?
The Motley Fool · 5d ago
Analysts Offer Insights on Healthcare Companies: Ramsay Health Care (OtherRMSYF) and Recursion Pharmaceuticals (RXRX)
TipRanks · 6d ago
Recursion Pharmaceuticals’ Earnings Call Highlights Growth
TipRanks · 03/04 00:37
Recursion Pharmaceuticals (NasdaqGS:RXRX) Surges 6% Following US$500 Million Follow-On Equity Offering
Simply Wall St · 03/03 17:49
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
Benzinga · 03/03 16:19
Weekly Report: what happened at RXRX last week (0224-0228)?
Weekly Report · 03/03 09:21
Company News for Mar 3, 2025
Barchart · 03/03 03:56
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip
Barchart · 03/02 19:40
This Just In: Analysts Are Boosting Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Outlook for This Year
Simply Wall St · 03/02 13:23
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday
Benzinga · 03/01 10:06
Recursion Pharmaceuticals Reports Mixed 2024 Financial Results
TipRanks · 03/01 04:10
More
Webull provides a variety of real-time RXRX stock news. You can receive the latest news about Recursion Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.